Ovid Therapeutics Inc. (OVID) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Ovid Therapeutics Inc. (OVID) closed at USD 2.19 on 2026-10-14, a change of +47 % over the past year, with a market capitalization of USD 441.37M.

Ovid Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Ovid Therapeutics Inc. key figures

Previous close

USD 2.19 (2026-10-14)

1-year change

+47 %

Market cap

USD 441.37M

Enterprise value

USD 336.87M

P/E ratio (trailing)

-9.83

P/E ratio (forward)

-6.03

EPS (trailing)

-0.23

EPS (forward)

-0.38

PEG ratio

n/a

Price to book

1.99

Revenue growth

-88.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.15

Employees

23

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Ovid Therapeutics Inc.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Ovid Therapeutics Inc. and compare it with other stocks.